Cargando…

A novel prothrombin time method to measure all non-vitamin K-dependent oral anticoagulants (NOACs)

BACKGROUND: There is a clinical need for point-of-care (POC) methods for non-vitamin K-dependent oral anticoagulants (NOACs). We modified a routine POC procedure: Zafena’s Simple Simon™ PT-INR, a room-temperature, wet-chemistry prothrombin time method of the Owren-type. METHODS: To either increase o...

Descripción completa

Detalles Bibliográficos
Autores principales: Lindahl, Tomas L., Arbring, Kerstin, Wallstedt, Maria, Rånby, Mats
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5649322/
https://www.ncbi.nlm.nih.gov/pubmed/28891412
http://dx.doi.org/10.1080/03009734.2017.1370040
_version_ 1783272532867022848
author Lindahl, Tomas L.
Arbring, Kerstin
Wallstedt, Maria
Rånby, Mats
author_facet Lindahl, Tomas L.
Arbring, Kerstin
Wallstedt, Maria
Rånby, Mats
author_sort Lindahl, Tomas L.
collection PubMed
description BACKGROUND: There is a clinical need for point-of-care (POC) methods for non-vitamin K-dependent oral anticoagulants (NOACs). We modified a routine POC procedure: Zafena’s Simple Simon™ PT-INR, a room-temperature, wet-chemistry prothrombin time method of the Owren-type. METHODS: To either increase or decrease NOAC interference, two assay variants were devised by replacing the standard 10 µL end-to-end capillary used to add the citrated plasma sample to 200 µL of prothrombin time (PT) reagent by either a 20 µL or a 5 µL capillary. All assay variants were calibrated to show correct PT results in plasma samples from healthy and warfarin-treated persons. RESULTS: For plasmas spiked with dabigatran, apixaban, or rivaroxaban, the 20 µL variant showed markedly higher PT results than the 5 µL. The effects were even more pronounced at room temperature than at +37 °C. In plasmas from patients treated with NOACs (n = 30 for each) there was a strong correlation between the PT results and the concentration of NOACs as determined by the central hospital laboratory. For the 20 µL variant the PT response of linear correlation coefficient averaged 0.90. The PT range was INR 1.1–2.1 for dabigatran and apixaban, and INR 1.1–5.0 for rivaroxaban. Using an INR ratio between the 20 µL and 5 µL variants (PTr20/5) made the NOAC assay more robust and independent of the patient sample INR value in the absence of NOAC. Detection limits were 80 µg/L for apixaban, 60 µg/L for dabigatran, and 20 µg/L for rivaroxaban. CONCLUSIONS: A wet-chemistry POC PT procedure was modified to measure the concentrations of three NOACs using a single reagent.
format Online
Article
Text
id pubmed-5649322
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-56493222017-10-27 A novel prothrombin time method to measure all non-vitamin K-dependent oral anticoagulants (NOACs) Lindahl, Tomas L. Arbring, Kerstin Wallstedt, Maria Rånby, Mats Ups J Med Sci Original Articles BACKGROUND: There is a clinical need for point-of-care (POC) methods for non-vitamin K-dependent oral anticoagulants (NOACs). We modified a routine POC procedure: Zafena’s Simple Simon™ PT-INR, a room-temperature, wet-chemistry prothrombin time method of the Owren-type. METHODS: To either increase or decrease NOAC interference, two assay variants were devised by replacing the standard 10 µL end-to-end capillary used to add the citrated plasma sample to 200 µL of prothrombin time (PT) reagent by either a 20 µL or a 5 µL capillary. All assay variants were calibrated to show correct PT results in plasma samples from healthy and warfarin-treated persons. RESULTS: For plasmas spiked with dabigatran, apixaban, or rivaroxaban, the 20 µL variant showed markedly higher PT results than the 5 µL. The effects were even more pronounced at room temperature than at +37 °C. In plasmas from patients treated with NOACs (n = 30 for each) there was a strong correlation between the PT results and the concentration of NOACs as determined by the central hospital laboratory. For the 20 µL variant the PT response of linear correlation coefficient averaged 0.90. The PT range was INR 1.1–2.1 for dabigatran and apixaban, and INR 1.1–5.0 for rivaroxaban. Using an INR ratio between the 20 µL and 5 µL variants (PTr20/5) made the NOAC assay more robust and independent of the patient sample INR value in the absence of NOAC. Detection limits were 80 µg/L for apixaban, 60 µg/L for dabigatran, and 20 µg/L for rivaroxaban. CONCLUSIONS: A wet-chemistry POC PT procedure was modified to measure the concentrations of three NOACs using a single reagent. Taylor & Francis 2017-08 2017-09-11 /pmc/articles/PMC5649322/ /pubmed/28891412 http://dx.doi.org/10.1080/03009734.2017.1370040 Text en © 2017 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. http://creativecommons.org/licenses/by/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Articles
Lindahl, Tomas L.
Arbring, Kerstin
Wallstedt, Maria
Rånby, Mats
A novel prothrombin time method to measure all non-vitamin K-dependent oral anticoagulants (NOACs)
title A novel prothrombin time method to measure all non-vitamin K-dependent oral anticoagulants (NOACs)
title_full A novel prothrombin time method to measure all non-vitamin K-dependent oral anticoagulants (NOACs)
title_fullStr A novel prothrombin time method to measure all non-vitamin K-dependent oral anticoagulants (NOACs)
title_full_unstemmed A novel prothrombin time method to measure all non-vitamin K-dependent oral anticoagulants (NOACs)
title_short A novel prothrombin time method to measure all non-vitamin K-dependent oral anticoagulants (NOACs)
title_sort novel prothrombin time method to measure all non-vitamin k-dependent oral anticoagulants (noacs)
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5649322/
https://www.ncbi.nlm.nih.gov/pubmed/28891412
http://dx.doi.org/10.1080/03009734.2017.1370040
work_keys_str_mv AT lindahltomasl anovelprothrombintimemethodtomeasureallnonvitaminkdependentoralanticoagulantsnoacs
AT arbringkerstin anovelprothrombintimemethodtomeasureallnonvitaminkdependentoralanticoagulantsnoacs
AT wallstedtmaria anovelprothrombintimemethodtomeasureallnonvitaminkdependentoralanticoagulantsnoacs
AT ranbymats anovelprothrombintimemethodtomeasureallnonvitaminkdependentoralanticoagulantsnoacs
AT lindahltomasl novelprothrombintimemethodtomeasureallnonvitaminkdependentoralanticoagulantsnoacs
AT arbringkerstin novelprothrombintimemethodtomeasureallnonvitaminkdependentoralanticoagulantsnoacs
AT wallstedtmaria novelprothrombintimemethodtomeasureallnonvitaminkdependentoralanticoagulantsnoacs
AT ranbymats novelprothrombintimemethodtomeasureallnonvitaminkdependentoralanticoagulantsnoacs